• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Biosimilars Rheumatology Roundup for January 2023—Podcast Edition

Article

On this episode of Not So Different, we reminisce about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.

On this episode of Not So Different, we reminisced about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.

Show notes

US Welcomes First Adalimumab Biosimilar, Amjevita

https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita

Canada Approves High-Concentration Humira Biosimilar

https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar

Celltrion Submits BLA for Infliximab Biobetter

https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter

FDA Accepts BLA for Alvotech Ustekinumab Biosimilar

https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar

Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study

https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study

China's NMPA Approves Tocilizumab Biosimilar

https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar

US Welcomes First Adalimumab Biosimilar, Amjevita

https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita

Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?

https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar-

Phase 1 Trial for Alvotech Golimumab Biosimilar Begins

https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins

Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis

https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis

Related Videos
Lakesha Farmer from Cencora
Prerakkumar Parikh, PharmD
Chelsee Jensen, PharmD, BCPS
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, executive director of the Biosimilars Forum
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Paul Reider
Jeffrey Casberg
Related Content
© 2024 MJH Life Sciences

All rights reserved.